Publications by authors named "Jean-Christophe Delain"
Article Synopsis
- Antisynthetase syndrome is a rare and serious disease that affects multiple organs, leading to muscle weakness, lung issues, skin problems, and joint inflammation, typically treated with corticosteroids and immunosuppressants.
- The case study discusses a 56-year-old Algerian woman with multiple drug resistance to traditional treatments, who responded well to subcutaneous immunoglobulin therapy, showing significant improvement in muscle strength and reduced immune deficiency within months.
- This suggests that subcutaneous immunoglobulin treatment could be an effective alternative for patients with hard-to-treat antisynthetase syndrome, offering better compliance and fewer side effects compared to standard therapies.
Subcutaneous immunoglobulin (SCIg) therapy is indicated in primary and secondary immunodeficiency diseases. Its use in practice is being extended to autoimmune diseases. Few studies investigated the feasibility and safety of SCIg in these rare conditions.
View Article and Find Full Text PDFIntroduction: Inclusion body myositis (IBM) is a slowly progressive degenerative inflammatory disorder affecting both proximal and distal muscles. Immunosuppressive therapies are generally ineffective in the treatment of this disorder, and most patients are resistant to steroid therapy. Some benefits with mild improvement were observed with intravenous immunoglobulin (IVIg), particularly in patients with severe dysphagia.
View Article and Find Full Text PDFArticle Synopsis
- Immunoglobulin (IG) therapy is used to treat a variety of diseases, including immunodeficiencies and autoimmune conditions, and can be administered either intravenously or subcutaneously.
- While IG therapy has shown effectiveness in many studies, it can cause a range of adverse reactions, from mild symptoms like headaches and nausea to severe issues such as migraines and renal impairment.
- The paper outlines all potential side effects of IG therapy, offers management guidelines for these reactions, and evaluates the opinions of experts based on evidence categorized using the GRADE system.
Polymyositis is a rare debilitating condition characterized by chronic inflammation and muscle weakness. Standard treatments include corticosteroids and immunosuppressants; however, resistance to these regimens may develop. Intravenous immunoglobulins (IVIg) are thus recommended for patients with drug-resistant polymyositis.
View Article and Find Full Text PDF